Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
Rheumatology 2024 doi 10.1093/rheumatology/keae060 Epub ahead of print
This post hoc analysis of the SPIRIT-H2H study showed that patients with PsA that were treated with ixekizumab had significantly higher rates of symptom resolution versus adalimumab at Weeks 12 and 52 in distal interphalangeal joint disease and nail PsO.
McGonagle, et al. assessed patients for joint tenderness and joint swelling at baseline and at weeks 4, 8, 12, 16, 24, 32, 40 and 52. They also assessed fingernail PsO at baseline and at weeks 12, 16, 24, 32, 40 and 52. Simultaneous resolution of DIP joint involvement and resolution of adjacent nail PsO was assessed at weeks 12, 16, 24, 32, 40 and 52.
Keywords:
